Literature DB >> 25648194

Invasive mold infections in lung and heart-lung transplant recipients: Stanford University experience.

R Vazquez1, M C Vazquez-Guillamet, J Suarez, J Mooney, J G Montoya, G S Dhillon.   

Abstract

BACKGROUND: Recipients of lung transplantation (LT) and heart-lung transplantation (HLT) are at increased risk of infection, including invasive mold infections (IMIs). The clinical presentation, radiographic correlates, and outcomes of Aspergillus and non-AspergillusIMIs in this population have not been well documented.
METHODS: LT and HLT recipients diagnosed with IMIs between 1990 and 2012 were identified using the Stanford Translational Research Integrated Database Environment and Stanford LT and HLT clinical database. Recipient clinical and radiographic characteristics were obtained via retrospective review of medical records and compared between Aspergillus and non-Aspergillus mold recipients. Risk factors for mortality were identified using multivariate logistic regression analysis.
RESULTS: During the study period, 87 (14%) transplant recipients were diagnosed with IMIs. Aspergillus species were isolated in 63 (72%) and non-Aspergillus molds in 24 (28%) recipients. No significant difference was seen in presenting symptoms or radiographic findings between Aspergillus and non-Aspergillus mold recipients. Median time to diagnosis was 363 days in the Aspergillus group and 419 days in the non-Aspergillus group, with dissemination occurring only within the non-Aspergillus group (12.5%). Overall 90-day and 1-year mortality following IMI was 24% and 44%. One-year mortality was increased in the non-Aspergillus group (39.5% vs. 60.5%, P = 0.03).
CONCLUSIONS: There is significant overlap in risk factors, presentation, and radiographic patterns in IMI in LT or HLT recipients. Non-Aspergillus molds were more likely to present late, with disseminated disease, and portend increased 1-year mortality.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Aspergillus; heart-lung transplant; invasive mold infections; lung transplant; non-Aspergillus

Mesh:

Substances:

Year:  2015        PMID: 25648194     DOI: 10.1111/tid.12362

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  7 in total

1.  Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study.

Authors:  Oluwatoyosi A Onwuemene; Steven C Grambow; Chetan B Patel; Robert J Mentz; Carmelo A Milano; Joseph G Rogers; Ara D Metjian; Gowthami M Arepally; Thomas L Ortel
Journal:  J Clin Apher       Date:  2018-03-10       Impact factor: 2.821

Review 2.  Fungal Infections After Lung Transplantation.

Authors:  Cassie C Kennedy; Raymund R Razonable
Journal:  Clin Chest Med       Date:  2017-05-20       Impact factor: 2.878

Review 3.  Fungal infections in lung transplantation.

Authors:  Palash Samanta; Cornelius J Clancy; M Hong Nguyen
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

Review 4.  Pulmonary Infections in Immunocompromised Hosts: Clinical.

Authors:  Cristina Vazquez Guillamet; Joe Le Hsu; Gundeep Dhillon; Rodrigo Vazquez Guillamet
Journal:  J Thorac Imaging       Date:  2018-09       Impact factor: 3.000

5.  Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States.

Authors:  Monica E D'Arcy; Ruth M Pfeiffer; Donna R Rivera; Gregory P Hess; Elizabeth K Cahoon; Sarah T Arron; Isaac Brownell; Edward W Cowen; Ajay K Israni; Matthew A Triplette; Elizabeth L Yanik; Eric A Engels
Journal:  JAMA Dermatol       Date:  2020-07-01       Impact factor: 10.282

Review 6.  Strategies for the Prevention of Invasive Fungal Infections after Lung Transplant.

Authors:  Roni Bitterman; Tina Marinelli; Shahid Husain
Journal:  J Fungi (Basel)       Date:  2021-02-07

7.  β-d-Glucan and Aspergillus Galactomannan assays in the diagnosis of invasive fungal infections.

Authors:  Mahadevan Kumar; M Mugunthan
Journal:  Med J Armed Forces India       Date:  2017-11-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.